Skip to Main Content

Good morning, one and all. Damian Garde here, filling in for Ed Silverman with your requisite helping of morning headlines. It’s Friday, as you undoubtedly know, which means your week, likely laden with meetings, deadlines, and other sundry horrors of working life, is coming to a close. Before you set off on a weekend we hope is devoid of drug industry distraction, settle in with one of those cups of stimulation — iced, perhaps — and enjoy these tidbits from around the pharma world.

Merck shattered analysts’ profit predictions on the strength of its star cancer therapy, Reuters tells us, as sales of Keytruda nearly tripled year over year. Amid the changing sands in immuno-oncology, Merck remains in the lead thanks in part to setbacks for rivals Bristol-Myers Squibb, Roche, and AstraZeneca. And on the topic of earnings, if you’re keen to dig into what has been an interesting quarter for biopharma, join STAT for a live chat today at noon ET.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!